Theralase Technologies Inc. V.TLT

Q3 2024 Earnings Call Transcript

[Oden6570]

Theralase Technologies Inc. (TLTFF) Q3 2024 Earnings Call Transcript | Seeking Alpha

[Oden6570]

In 68% of cases or approximately 7 out of 10 patients, Theralase has been able to completely destroy the cancer in their bladder. This is extremely encouraging for patients who have had no other treatment options other than removal of their bladder and the morbidity and mortality risks associated with that significant surgery. Clinical data is still being collected, but all indications demonstrate

[wildbird1]

Thanks Oden6570... In this transcript, TLT said...'' Theralase has clinical study results that not only exceed the international bladder cancer group's guidelines used for recent FDA approval, but outperform all currently approved FDA treatments and even treatments in the development pipeline''. Because Ruvidar outperform all currently approved treatments(these treatments

[DJDawg]

Reading the transcript it was interesting to read about the preparation for GBM and NSCLC studies. They specifically say the the prep has been done for GBM and they are working on it for NSCLC. That is interesting as that means they are further head with GBM. Plus GBM is ugly. 15 m average life expectancy from time of diagnosis. It would be considered a priority kind of condition to get new